中文摘要：

Artemisinin，首要的抗疟药药的关键成分，每年有大需求。本国的植物，生产 artemisinin 的小数量，作为它的主要来源留下并且因此导致 artemisinin 的短供应。加强的努力被执行了提高 artemisinin 生产。然而，经由在 artemisinin 生合成分支小径的 overexpressing 或下面调整的基因，平淡的新陈代谢的工程策略不是很有效的是需要。腺的能分泌的毛状体， Artemisia annua L 的表面上的 artemisinin 生合成的地点。（ A。annua ) ，是为增加 artemisinin 产量的新目标。一般来说，在 A 的腺的能分泌的毛状体的人口和形态学。annua (AaGSTs ) 断然经常与 artemisinin 内容被相关。AaGSTs 的改进理解将为增加导出植物的 artemisinin 使机会清楚些。在 A 的毛状体的这个评论文章愿望刷新分类。annua 并且关于 AaGSTs 和 artemisinin 提供最近的成就的概述。为了有 AaGSTs，与毛状体形态学被联系的因素和密度愿望的完整的理解，不得不进一步被调查，例如基因， microRNAs 和植物激素。这评论的目的到过(1 ) 更新在 AaGSTs 和 artemisinin 之间的关系的知识，并且(2 ) 建议新大街由利用潜在的 biofactories 增加 artemisinin 产量， AaGSTs。

英文摘要：

Artemisinin, the key ingredient of first-line antimalarial drugs, has large demand every year. The native plant, which produces small quantities of artemisi- nin, remains as its main source and thus results in a short supply of artemisinin. Intensified efforts have been carried out to elevate artemisinin production. However, the routine metabolic engineering strategy, via overexpressing or down-regulating genes in artemisinin biosynthesis branch pathways, was not very effective as desired. Glandular secretory trichomes, sites of artemisinin biosynthesis on the surface of Artemisia annua L. （A. annua）, are the new target for increasing artemisinin yield. In general, the population and morphology of glandular secretory tri- chomes in A. annua （AaGSTs） are often positively corre- lated with artemisinin content. Improved understanding of AaGSTs will shed light on the opportunities for increasing plant-derived artemisinin. This review article will refresh classification of trichomes in A. annua and provide an overview of the recent achievements regarding AaGSTs and artemisinin. To have a full understanding of AaGSTs, factors that are associated with trichome morphology and density will have to be further investigated, such as genes, microRNAs and phytohormones. The purpose of this review was to （1） update the knowledge of the relation between AaGSTs and artemisinin, and （2） propose new avenues to increase artemisinin yield by harnessing the potential biofactories, AaGSTs.